PROSTACOX : Metastatic Prostate Chemotherapy

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Rouen
• Treatments: Celecoxib; Docetaxel

Criteria

Inclusion Criteria:

• metastatic prostate cancer

• ASCO progression criteria

Exclusion Criteria:

• other prostate chemotherapy